Dr. Elizabeth Plimack on Consideration Regarding Nivolumab in RCC


Elizabeth Plimack, MD, Director of Genitourinary Clinical Research, Associate Professor, department of hematology/oncology, Fox Chase Cancer Center, discusses which patients should receive nivolumab and how it and other novel agents should be sequenced in renal cell carcinoma (RCC).

Most RCC patients should receive nivolumab, said Plimack. Very few patients are ineligible, however those with autoimmune diseases, even if it is well-controlled, should not receive the drug.

Patients are living longer with RCC and therefore most will receive multiple novel agents, including nivolumab and cabozantinib, at some point during the duration of their treatment. The question of when each patient should receive which drug is still being determined, said Plimack.

Related Videos
Rohan Garje, MD
Sarah E. S. Leary, MD, MS, attending physician, medical director, Pediatric Brain Tumor Program, Seattle Children’s Hospital; professor, Department of Pediatrics, University of Washington School of Medicine
Rita Nanda, MD
Vikram Narayan, MD
Daniel Olson, MD
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai